Tuberculosis Drug Resistance and Treatment Adherence Pose Major Challenges in Mexico
Mexico faces significant hurdles in controlling tuberculosis (TB), particularly with the rise of drug-resistant strains and challenges in ensuring patients adhere to lengthy treatment regimens. These factors contribute to the ongoing public health burden of the disease, which remains one of the world’s most lethal infectious diseases.
According to recent data, approximately 10 million cases of tuberculosis are estimated to occur globally each year, with 8.2 million reported. Sadly, TB continues to claim around 1.3 million lives annually. In Mexico alone, nearly 28,000 cases have been registered so far in 2024.
A recent videoconference organized by the Escuela de Salud Pública de México (ESPM) highlighted the current epidemiological situation of tuberculosis in both the world and Mexico, as well as the difficulties and strategies for improving its control. Dr. Marcela Verónica Muñoz Torrico, a clinical advisor with the Global TB Network, presented the findings.
The disease disproportionately affects men of working age and a substantial percentage of cases are linked to co-existing conditions such as diabetes, HIV/AIDS, and malnutrition. These comorbidities increase patient vulnerability and complicate treatment, underscoring the need for integrated care approaches.
Currently, Mexico employs a standard six-month treatment protocol based on rifampicin, isoniazid, pyrazinamide, and ethambutol. However, the World Health Organization (WHO) has approved new therapeutic strategies to shorten treatment duration for drug-sensitive tuberculosis.
One promising approach is a four-month regimen utilizing rifapentine and moxifloxacin, which is recommended for specific patient groups. These advancements offer the potential to improve treatment outcomes and reduce the burden on healthcare systems.
The increasing prevalence of drug resistance, including the emergence of extensively drug-resistant (TB-XDR) strains – those resistant to all existing medications – is a major concern. Drug-resistant TB transmits in the same way as drug-sensitive TB, making early detection and appropriate treatment crucial to prevent further spread.
Efforts to consolidate a strategic approach to multidrug-resistant tuberculosis (MDR-TB) and maintain the availability of second-line drugs are ongoing. Strengthening a network of experts in TB-MDR is also a priority to ensure adequate care for patients with resistant forms of the disease.
The challenges in Mexico reflect a global trend, and continued vigilance, research, and investment in TB control programs are essential to protect public health. The findings emphasize the importance of addressing both the medical and social determinants of tuberculosis to achieve lasting progress.
